National consortium to examine the impacts of arising SARS-CoV-2 mutations Kumar Jeetendra | January 16, 2021 The’G2P-UK’ National Virology Consortium will study how mutations in the virus affect key outcomes like how transmissible it is, the seriousness of COVID-19 it causes, and the potency of vaccines and treatments. The Consortium will bring together leading virologists from 10 research institutions. They will work together with the COVID-19 Genomics UK (COG-UK) consortium, which …
Substances in tick spit actuate insusceptible reaction smothering proteins in cattles Kumar Jeetendra | January 28, 2021 Scientists from Hokkaido University, Japan and Universidade Federal do Rio Grande do Sul and Universidade Federal do Rio de Janeiro, Brazil, have revealed that substances in tick saliva trigger immune response-suppressing proteins in cows that facilitates the transmission of tick-borne diseases. The finding was published in the journal Scientific Reports and could assist in the …
New gene based vaccine procedure gets award from the Bill and Melinda Gates Foundation Kumar Jeetendra | January 29, 2021 The AAVCOVID vaccine application, a novel gene-based vaccine plan that utilizes an adeno-associated virus (AAV) vector, was granted an award for up to $2.1 million from the Bill & Melinda Gates Foundation. The grant will assist the effort to bring further preclinical validation into the AAV vaccine platform. An AAVCOVID vaccine candidate is set to …
New device empowers study of SARS-CoV-2 mutant range by ultrasequencing Kumar Jeetendra | February 15, 2021 SARS-CoV-2 genome is three times larger than flu genome. Both consist of NRA molecules which mutate when replicate. It is essential to know its mutant spectrum, in other words, its”fingerprints”, to achieve an appropriate treatment that reduces its infectivity -the capacity of pathogens to invade organisms and cause infections-, since its composition of variables could …
FDA issues emergency use approval for T-Detect COVID Test Kumar Jeetendra | March 7, 2021 Now, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for its T-Detect COVID Exam developed by Adaptive Biotechnologies. The T-Detect COVID Evaluation is a next generation sequencing established (NGS) test to assist in identifying people with an adaptive T cell immune response to SARS-CoV-2, indicating recent or prior infection with SARS-CoV-2. …
Mosquito protein study could prompt therapeutics against dangerous viruses Kumar Jeetendra | March 11, 2021 The researchers found that AEG12 works by destabilizing the viral envelope, breaking its protective covering. Although the protein doesn’t affect viruses that don’t have an envelope, such as the ones that cause pink eye and bladder ailments, the findings could lead to therapeutics against viruses which affect millions of people around the world. The research …
Killing antibodies actuated by COVID-19 vaccines less successful against new variants Kumar Jeetendra | March 15, 2021 SARS-CoV-2, the virus that causes COVID-19, has mutated through the pandemic. New variants of this virus have arisen around the world, including variants that might possess increased capacity to spread or evade the immune system. Such variations have been identified in California, Denmark, the U.K., South Africa and Brazil/Japan. Recognizing how well the COVID-19 vaccines …
Study offers understanding into metabolic pathways hijacked by SARS-CoV-2 for viral replication Kumar Jeetendra | March 16, 2021 When SARS-CoV-2, the virus which causes COVID-19, infects a human cell, it quickly begins to replicate by seizing the cell’s existing metabolic machinery. The infected cells churn out thousands of viral genomes and proteins while halting the creation of their own sources. Researchers from Brigham and Women’s Hospital, Massachusetts General Hospital (MGH), and the Broad …
Study uncovers immune defense system that shields the lungs from viral diseases Kumar Jeetendra | March 18, 2021 Scientists have discovered a previously unknown arm of the immune defense system that protects the lung from lethal viral infections. Respiratory diseases caused by viruses such as influenza A and SARS-CoV-2 cause harm not only through their own activities, but also from collateral damage as the immune system reacts to combat the infection. A timely …
Bacteria residing within inside tumor cells can support malignant growth immunotherapy Kumar Jeetendra | March 22, 2021 Cancer immunotherapy may get a boost from an unexpected direction: bacteria residing within tumor cells. The study may also help clarify the connection between immunotherapy and the intestine microbiome, describing the findings of earlier research that the microbiome impacts the success of immunotherapy. Immunotherapy remedies of the last decade or so have dramatically improved healing …
Study uncovers molecular mechanisms of drug resistance in Mycobacterium tuberculosis Kumar Jeetendra | April 9, 2021 A consortium of researchers from Russia, Belarus, Japan, Germany and France led by a Skoltech scientist have uncovered the way by which Mycobacterium tuberculosis survives in iron-deficient states by using rubredoxin B, a protein by a rubredoxin family that play an essential role in adaptation to changing environmental conditions. The new study is part of …
Small SARS-CoV-2 protein may have huge ramifications for future COVID-19 medicines Kumar Jeetendra | April 12, 2021 A very small protein of SARS-CoV-2, the coronavirus that gives rise to COVID-19, may have big implications for future therapies, according to a team of Penn State researchers. Using a novel toolkit of approaches, the scientists uncovered the first full structure of the Nucleocapsid (N) protein and discovered how antibodies from COVID-19 patients interact with …
